NASDAQ:COAG

Hemab Therapeutics Pulls Back After 53% IPO Surge
·

Hemab Therapeutics Pulls Back After 53% IPO Surge

Hemab Therapeutics (COAG) will open Wednesday pre-market at $27.47, up 53% from its $18 IPO price. The company raised $346.7 million in its May IPO, ending March with $163.5 million in cash before IPO proceeds. Hemab plans a pivotal Phase 3 trial for its lead drug, sutacimig, in Glanzmann thrombasthenia in late 2026. CEO Benny Sørensen said data from key programs is expected by late 2026 or early 2027.
June 3, 2026

Stock Market Today

  • Ramsdens Interim Results Show Strong Profit Beat Amid Gold and Travel Challenges
    June 3, 2026, 5:54 AM EDT. Ramsdens Holdings (LON:RFX) reported robust Interim Results, surpassing market expectations despite gold price fluctuations and travel disruptions. The company issued multiple profit upgrades over recent months, underscoring stronger-than-anticipated business performance. Ramsdens generated higher first-half profits than anticipated for the full financial year 2025. Shares are expected to rebound above the 470p level last seen in January. This reflects investor confidence in Ramsdens' resilience amid volatile market conditions and operational hurdles related to travel restrictions and gold price volatility.